Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO

Valeant Pharmaceuticals International, Inc. VRX today announced the appointment of J. Michael Pearson, currently Valeant's Chief Executive Officer, as Chairman of the Board of Directors, replacing Robert A. Ingram, who remains on the Valeant Board as an independent Board Director and Lead Director. Mr. Pearson will continue in his role as CEO and has agreed to extend his contract through to February 2017.